Found: 35
Select item for more details and to access through your institution.
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.
- Published in:
- Communications Biology, 2021, v. 4, n. 1, p. 1, doi. 10.1038/s42003-021-02215-w
- By:
- Publication type:
- Article
Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma.
- Published in:
- Laryngoscope, 2010, v. 120, n. 12, p. 2456, doi. 10.1002/lary.21145
- By:
- Publication type:
- Article
RNAi phenotype profiling of kinases identifiespotential therapeutic targets in Ewing¿s sarcoma.
- Published in:
- Molecular Cancer, 2010, v. 9, p. 218, doi. 10.1186/1476-4598-9-218
- By:
- Publication type:
- Article
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 636, doi. 10.1007/s10637-018-0668-8
- By:
- Publication type:
- Article
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 4, p. 870, doi. 10.1007/s10637-015-0242-6
- By:
- Publication type:
- Article
Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma.
- Published in:
- International Journal of Clinical Oncology, 2013, v. 18, n. 5, p. 934, doi. 10.1007/s10147-012-0475-8
- By:
- Publication type:
- Article
A phase II study of combination d aunorubicin, cytarabine (A ra‐c), and nilotinib (TA signa) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. 472, doi. 10.1002/ajh.26831
- By:
- Publication type:
- Article
Living with Cancer: an Educational Intervention in Cancer Patients Can Improve Patient-Reported Knowledge Deficit.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.
- Published in:
- PLoS ONE, 2015, v. 10, n. 7, p. 1, doi. 10.1371/journal.pone.0132831
- By:
- Publication type:
- Article
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 4, p. 1056, doi. 10.1007/s10637-012-9909-4
- By:
- Publication type:
- Article
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 6, p. 2334, doi. 10.1007/s10637-011-9774-6
- By:
- Publication type:
- Article
Activity of alemtuzumab in patients with CD52‐positive acute leukemia.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 12, p. 2645
- By:
- Publication type:
- Article
Recent developments in myelofibrosis.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2012, v. 2, p. 125, doi. 10.2147/blctt.s24960
- By:
- Publication type:
- Article
Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms.
- Published in:
- Molecular Diagnosis & Therapy, 2012, v. 16, n. 5, p. 269, doi. 10.1007/s40291-012-0006-3
- By:
- Publication type:
- Article
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
<sup>68</sup>Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262206
- By:
- Publication type:
- Article
<sup>68</sup>Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262206
- By:
- Publication type:
- Article
<sup>68</sup>Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262194
- By:
- Publication type:
- Article
<sup>68</sup>Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262206
- By:
- Publication type:
- Article
<sup>68</sup>Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262206
- By:
- Publication type:
- Article
<sup>68</sup>Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.121.262206
- By:
- Publication type:
- Article
A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 2, p. 463, doi. 10.1007/s00280-012-2019-3
- By:
- Publication type:
- Article
Dose–response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-71246-w
- By:
- Publication type:
- Article
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. E626, doi. 10.1002/ajh.24866
- By:
- Publication type:
- Article
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome.
- Published in:
- Dermatology Reports, 2011, v. 3, n. 3, p. 125, doi. 10.4081/dr.2011.e55
- By:
- Publication type:
- Article
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, p. 1, doi. 10.1186/s13045-015-0211-8
- By:
- Publication type:
- Article
Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
- Published in:
- Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 1, doi. 10.1186/1756-8722-7-18
- By:
- Publication type:
- Article
Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
- Published in:
- 2020
- By:
- Publication type:
- journal article
PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation.
- Published in:
- British Journal of Haematology, 2008, v. 140, n. 3, p. 344, doi. 10.1111/j.1365-2141.2007.06920.x
- By:
- Publication type:
- Article
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10073-w
- By:
- Publication type:
- Article
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 15, p. 2321, doi. 10.1002/cncr.34800
- By:
- Publication type:
- Article
Synergistic Targeting of AML Stem/Progenitor Cells With IAP Antagonist Birinapant and Demethylating Agents.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 2, p. 1, doi. 10.1093/jnci/djt440
- By:
- Publication type:
- Article
Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2019, v. 9, p. 1, doi. 10.3389/fonc.2019.01205
- By:
- Publication type:
- Article
Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
- Published in:
- Current Hematologic Malignancy Reports, 2012, v. 7, n. 1, p. 78, doi. 10.1007/s11899-011-0107-9
- By:
- Publication type:
- Article